Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.15 EUR -0.94% Market Closed
Market Cap: 511.9m EUR

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Valneva SE

Revenue
229.4m EUR
Cost of Revenue
-140.5m EUR
Gross Profit
88.9m EUR
Operating Expenses
-33.6m EUR
Operating Income
55.3m EUR
Other Expenses
-38m EUR
Net Income
17.3m EUR

Margins Comparison
Valneva SE Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
FR
Valneva SE
PAR:VLA
511.9m EUR
39%
24%
8%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
70%
29%
8%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
62%
22%
12%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
78%
38%
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
86%
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
121.1B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
87%
30%
31%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
XBRU:ARGX
32.9B EUR
90%
-1%
38%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Valneva SE Competitors

Country Company Market Cap ROE ROA ROCE ROIC
FR
Valneva SE
PAR:VLA
511.9m EUR
9%
3%
16%
17%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
62%
3%
17%
20%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
68%
4%
10%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
2%
1%
22%
15%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
-3%
-2%
23%
-102%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
121.1B AUD
15%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
16%
12%
13%
65%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
32.9B EUR
20%
18%
0%
-11%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.